The Patent Finder
US

Pharmaceutical Formulations of a Pan-Raf Kinase Inhibitor and Processes for Their Preparation

US 10,426,782 In force
OverviewFamilyAssignmentsSources & methods

Also listed on Biogen Idec International GmbH, an earlier holder on the record. The recorded assignments below show how it moved.

Term ends Jun 23, 2035 · High confidence

Filed Sep 23, 2016 as application 15/128,714 · Granted Oct 1, 2019
Base term plus 89 days of patent term adjustment (USPTO delay)
Today
20 years from filing
2015 2035
Clock starts
Mar 26, 2015
Term ends
Jun 23, 2035
Granted
Oct 1, 2019
base term patent term adjustment fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
89
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
2
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 89 days past its 20-year base term on prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Mar 26, 2015, when application PCT/US2015/022792, the earliest non-provisional in its chain, was filed (this one was filed Sep 23, 2016)Mar 26, 2035High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+89 days, USPTO patent term adjustment recordJun 23, 2035High confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderJun 23, 2035High confidence

This family

Application PCT/US2015/022792PCT application
no patent term
no patent term
US 10,426,782this patent
Jun 2035
Jun 2035
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Oct 15, 2019
Reel 50715, frame 215
Bozon, Viviana; Galvin, Katherine M.Millennium Pharmaceuticals, Inc.Assignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 284
Formulation Technologies L.L.C.Biogen Idec Ma Inc.; Biogen Idec International GmbHAssignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 345
Takeda Pharmaceutical Company LimitedMillennium Pharmaceuticals, Inc.Assignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 376
Kodono, YukiTakeda Pharmaceutical Company LimitedAssignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 437
Chow, Ching-kuo J.Biogen Idec Ma Inc.Assignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 636
Biogen Ma Inc.Millennium Pharmaceuticals, Inc.Assignment of Assignor's Interest
Oct 15, 2019
Reel 50715, frame 665
Dinunzio, James CarloFormulation Technologies L.L.C.Assignment of Assignor's Interest
Oct 15, 2019
Reel 50718, frame 617
Brake, Rachel L.; Kannan, Karuppiah; Xu, QunliMillennium Pharmaceuticals, Inc.Assignment of Assignor's Interest
Oct 15, 2019
reel/frame not recorded
Formulation Technologies L.L.C.Biogen Idec Ma Inc.Assignment of Assignor's Interest
Oct 15, 2019
reel/frame not recorded
Formulation Technologies L.L.C.Biogen Idec International GmbHAssignment of Assignor's Interest
Mar 5, 2020
Reel 52026, frame 772
Millennium Pharmaceuticals, Inc.Dot Therapeutics-1, Inc.Assignment of Assignor's Interest
May 17, 2022
Reel 59936, frame 96
Dot Therapeutics-2, Inc.; Dot Therapeutics-1, Inc.Day One Biopharmaceuticals, Inc.Merger

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited